Regeneron Pharmaceuticals - REGN Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $989.36
Forecasted Upside: 0.72%
Number of Analysts: 21
Breakdown:
1 Sell Ratings
4 Hold Ratings
15 Buy Ratings
1 Strong Buy Ratings

^$982.29 As of 05/17/2024 01:00 AM ET

▲ +14.31 (1.48%)

1 month | 3 months | 12 months

Get New Regeneron Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for REGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for REGN

^$989.36

▲ +0.72% Upside Potential

This price target is based on 21 analysts offering 12 month price targets for Regeneron Pharmaceuticals in the last 3 months. The average price target is $989.36, with a high forecast of $1,189.00 and a low forecast of $720.00. The average price target represents a 0.72% upside from the last price of $982.29.

Current Consensus is Moderate Buy

The current consensus among 21 investment analysts is to moderate buy stock in Regeneron Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

1 strong buy ratings
15 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

11/24/2022

1 strong buy ratings
15 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

2/22/2023

1 strong buy ratings
15 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

5/23/2023

1 strong buy ratings
15 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

8/21/2023

1 strong buy ratings
15 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

11/19/2023

1 strong buy ratings
15 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

2/17/2024

1 strong buy ratings
15 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

4/17/2024

1 strong buy ratings
15 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

5/17/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/14/2024	Evercore ISI	Initiated Coverage	Outperform	$1,150.00	Low
5/13/2024	Evercore ISI	Upgrade	Strong-Buy		Low
5/3/2024	Cantor Fitzgerald	Reiterated Rating	Neutral ➝ Neutral	$925.00	Low
4/24/2024	TD Cowen	Boost Target	Buy ➝ Buy	$1,020.00 ➝ $1,030.00	Low
4/17/2024	UBS Group	Boost Target	Buy ➝ Buy	$1,090.00 ➝ $1,099.00	Low
4/15/2024	Cantor Fitzgerald	Reiterated Rating	Neutral ➝ Neutral	$925.00	Low
4/12/2024	Bank of America	Boost Target	Underperform ➝ Underperform	$710.00 ➝ $720.00	Low
4/9/2024	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$1,189.00	Low
4/3/2024	Truist Financial	Reiterated Rating	Buy ➝ Buy	$1,135.00	Low
3/26/2024	Truist Financial	Reiterated Rating	Buy ➝ Buy	$1,135.00	Low
3/13/2024	Morgan Stanley	Boost Target	Overweight ➝ Overweight	$1,104.00 ➝ $1,115.00	Low
3/12/2024	Sanford C. Bernstein	Initiated Coverage	Outperform	$1,125.00	Low
2/27/2024	Royal Bank of Canada	Boost Target	Outperform ➝ Outperform	$1,096.00 ➝ $1,184.00	Low
2/6/2024	Cantor Fitzgerald	Boost Target	Neutral ➝ Neutral	$850.00 ➝ $925.00	Low
2/5/2024	Royal Bank of Canada	Boost Target	Outperform ➝ Outperform	$1,076.00 ➝ $1,110.00	Low
2/5/2024	BMO Capital Markets	Boost Target	Outperform ➝ Outperform	$1,055.00 ➝ $1,082.00	Low
1/29/2024	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$1,076.00	Low
1/23/2024	Barclays	Boost Target	Overweight ➝ Overweight	$935.00 ➝ $1,020.00	Low
1/12/2024	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$884.00 ➝ $1,076.00	Low
1/9/2024	Cantor Fitzgerald	Reiterated Rating	Neutral ➝ Neutral	$850.00	Low
12/18/2023	Truist Financial	Reiterated Rating	Buy ➝ Buy	$1,045.00	Low
12/6/2023	TD Cowen	Boost Target	Outperform ➝ Outperform	$900.00 ➝ $1,000.00	Low
11/28/2023	Jefferies Financial Group	Boost Target	Buy ➝ Buy	$935.00 ➝ $937.00	Low
11/28/2023	Truist Financial	Reiterated Rating	Buy ➝ Buy	$1,045.00	Low
11/9/2023	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Hold	$800.00	Low
11/3/2023	Piper Sandler	Boost Target	Overweight ➝ Overweight	$885.00 ➝ $895.00	Low
11/3/2023	Royal Bank of Canada	Lower Target	Sector Perform ➝ Sector Perform	$847.00 ➝ $837.00	Low
11/3/2023	Morgan Stanley	Lower Target	Overweight ➝ Overweight	$915.00 ➝ $914.00	Low
11/3/2023	Raymond James	Upgrade	Market Perform ➝ Outperform	$950.00	N/A
10/16/2023	Cantor Fitzgerald	Boost Target	Neutral ➝ Neutral	$800.00 ➝ $850.00	Low
10/12/2023	Royal Bank of Canada	Boost Target	Sector Perform ➝ Sector Perform	$833.00 ➝ $847.00	Low
10/11/2023	Morgan Stanley	Boost Target	Overweight ➝ Overweight	$912.00 ➝ $915.00	Low
9/29/2023	Bank of America	Boost Target		$665.00 ➝ $680.00	Low
9/21/2023	Cantor Fitzgerald	Reiterated Rating	Neutral ➝ Neutral	$800.00	Low
9/15/2023	Argus	Boost Target	Buy ➝ Buy	$825.00 ➝ $920.00	Low
9/15/2023	Westpark Capital	Initiated Coverage	Hold		Low
8/21/2023	Canaccord Genuity Group	Upgrade	Hold ➝ Buy	$720.00 ➝ $992.00	Low
8/21/2023	Canaccord Genuity Group	Upgrade	Hold ➝ Buy	$720.00 ➝ $992.00	Low
8/21/2023	Royal Bank of Canada	Boost Target	Sector Perform ➝ Sector Perform	$820.00 ➝ $830.00	Low
8/21/2023	BMO Capital Markets	Boost Target	Outperform ➝ Outperform	$960.00 ➝ $985.00	Low
8/21/2023	Wells Fargo & Company	Boost Target	Overweight ➝ Overweight	$875.00 ➝ $980.00	Low
8/21/2023	Oppenheimer	Boost Target	Outperform ➝ Market Perform	$950.00 ➝ $1,050.00	Low
8/21/2023	Barclays	Boost Target	Overweight ➝ Overweight	$900.00 ➝ $925.00	Low
8/18/2023	Canaccord Genuity Group	Reiterated Rating	Hold ➝ Hold	$720.00	Low
8/16/2023	Truist Financial	Reiterated Rating	Buy ➝ Buy	$1,045.00	Low
8/7/2023	Barclays	Boost Target	Overweight ➝ Overweight	$888.00 ➝ $900.00	Low
8/4/2023	Morgan Stanley	Boost Target	Overweight ➝ Overweight	$897.00 ➝ $912.00	Low
8/4/2023	Royal Bank of Canada	Boost Target	Sector Perform ➝ Sector Perform	$818.00 ➝ $820.00	Low
8/4/2023	Oppenheimer	Boost Target	Outperform ➝ Outperform	$900.00 ➝ $950.00	Low
7/18/2023	BMO Capital Markets	Lower Target		$1,040.00 ➝ $960.00	Low
7/17/2023	Guggenheim	Lower Target		$935.00 ➝ $900.00	Low
6/28/2023	22nd Century Group	Reiterated Rating	Downgrade		Low
6/28/2023	500.com	Reiterated Rating	Maintains		Low
6/28/2023	VNET Group	Reiterated Rating	Downgrade		Low
6/28/2023	Truist Financial	Lower Target		$1,050.00 ➝ $1,045.00	Low
6/28/2023	Canaccord Genuity Group	Downgrade	Buy ➝ Hold	$953.00 ➝ $720.00	Low
6/28/2023	Royal Bank of Canada	Lower Target		$816.00 ➝ $789.00	Low
6/28/2023	Robert W. Baird	Lower Target		$800.00 ➝ $760.00	Low
6/28/2023	Wells Fargo & Company	Lower Target		$915.00 ➝ $875.00	Low
6/28/2023	Barclays	Lower Target		$915.00 ➝ $888.00	Low
6/9/2023	Royal Bank of Canada	Boost Target		$811.00 ➝ $816.00	Low
5/8/2023	Guggenheim	Lower Target		$960.00 ➝ $935.00	Low
5/5/2023	888	Reiterated Rating	Maintains		Low
5/5/2023	Morgan Stanley	Boost Target		$880.00 ➝ $927.00	Low
5/5/2023	SVB Securities	Lower Target		$976.00 ➝ $895.00	Low
5/3/2023	Truist Financial	Boost Target		$856.00 ➝ $1,050.00	Low
4/20/2023	TD Cowen	Boost Target	Outperform	$875.00 ➝ $885.00	Low
4/12/2023	Morgan Stanley	Lower Target		$883.00 ➝ $880.00	Low
3/31/2023	JPMorgan Chase & Co.	Boost Target	Overweight	$900.00 ➝ $950.00	Low
3/30/2023	Jefferies Financial Group	Boost Target		$925.00 ➝ $940.00	Low
3/29/2023	Bank of America	Boost Target	Underperform	$605.00 ➝ $650.00	Low
3/28/2023	Erste Group Bank	Reiterated Rating	Buy		Low
3/27/2023	SVB Leerink	Upgrade	Market Perform ➝ Outperform		Low
3/27/2023	SVB Securities	Upgrade	Market Perform ➝ Outperform	$834.00 ➝ $976.00	Low
3/24/2023	BMO Capital Markets	Boost Target		$1,025.00 ➝ $1,040.00	Low
3/24/2023	Wells Fargo & Company	Boost Target	Overweight	$860.00 ➝ $915.00	Low
3/24/2023	Robert W. Baird	Boost Target	Neutral	$756.00 ➝ $800.00	Low
3/24/2023	Barclays	Boost Target	Overweight	$815.00 ➝ $915.00	Low
3/24/2023	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$675.00 ➝ $925.00	Low
3/23/2023	Raymond James	Upgrade	Underperform ➝ Market Perform		Low
3/23/2023	EF Hutton Acquisition Co. I	Boost Target	Buy	$853.00 ➝ $862.00	Low
3/20/2023	Royal Bank of Canada	Lower Target		$806.00 ➝ $802.00	Low
3/14/2023	BMO Capital Markets	Boost Target	Outperform	$1,001.00 ➝ $1,025.00	Low
3/9/2023	Royal Bank of Canada	Boost Target	Sector Perform	$787.00 ➝ $806.00	Low
2/24/2023	EF Hutton Acquisition Co. I	Reiterated Rating	Buy	$853.00	Low
2/17/2023	Wells Fargo & Company	Boost Target	Overweight	$800.00 ➝ $860.00	Low
2/8/2023	EF Hutton Acquisition Co. I	Boost Target	Buy	$851.00 ➝ $853.00	Low
2/6/2023	Royal Bank of Canada	Lower Target	Sector Perform	$789.00 ➝ $787.00	Low
2/6/2023	SVB Leerink	Boost Target	Market Perform	$770.00 ➝ $834.00	Low
2/6/2023	Robert W. Baird	Boost Target		$670.00 ➝ $756.00	Low
1/30/2023	Cowen	Upgrade	Market Perform ➝ Outperform	$775.00 ➝ $875.00	Low
1/30/2023	Cowen	Upgrade	Market Perform ➝ Outperform	$775.00 ➝ $875.00	Low
1/24/2023	Morgan Stanley	Boost Target	Overweight	$868.00 ➝ $873.00	Low
1/20/2023	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$850.00	Low
1/11/2023	EF Hutton Acquisition Co. I	Reiterated Rating	Buy	$851.00	Low
11/11/2022	Guggenheim	Lower Target	Buy	$925.00 ➝ $915.00	Low
11/9/2022	Truist Financial	Boost Target		$790.00 ➝ $856.00	Low
11/4/2022	Morgan Stanley	Boost Target	Overweight	$851.00 ➝ $868.00	Low
11/4/2022	SVB Leerink	Boost Target	Market Perform	$756.00 ➝ $770.00	Low
11/3/2022	Piper Sandler	Lower Target	Overweight	$775.00 ➝ $765.00	Low
11/1/2022	EF Hutton Acquisition Co. I	Initiated Coverage	Buy	$851.00	Low
10/26/2022	Raymond James	Downgrade	Market Perform ➝ Underperform		Low
10/20/2022	Cowen	Boost Target		$655.00 ➝ $750.00	Low
10/20/2022	Cowen	Boost Target	Market Perform	$655.00 ➝ $750.00	Low
10/3/2022	The Goldman Sachs Group	Boost Target	Buy	$796.00 ➝ $970.00	Low
9/16/2022	Canaccord Genuity Group	Boost Target	Buy ➝ Buy	$700.00 ➝ $750.00	Low
9/13/2022	Piper Sandler	Boost Target	Overweight	$692.00 ➝ $775.00	Low
9/12/2022	Guggenheim	Boost Target		$740.00 ➝ $925.00	Low
9/12/2022	Wells Fargo & Company	Boost Target	Overweight	$735.00 ➝ $800.00	Low
9/9/2022	Truist Financial	Boost Target		$718.00 ➝ $790.00	Low
9/9/2022	SVB Leerink	Boost Target	Market Perform ➝ Market Perform	$630.00 ➝ $756.00	Low
9/9/2022	Barclays	Boost Target	Overweight	$735.00 ➝ $815.00	Low
9/9/2022	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$625.00 ➝ $851.00	Low
9/8/2022	Jefferies Financial Group	Upgrade	Underperform ➝ Hold	$536.00 ➝ $675.00	Low
8/9/2022	Cowen	Boost Target		$655.00	Low
8/4/2022	BMO Capital Markets	Boost Target	Outperform	$757.00 ➝ $788.00	Low
8/4/2022	Morgan Stanley	Boost Target	Equal Weight	$619.00 ➝ $625.00	Low
7/25/2022	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$630.00	Low
7/20/2022	Cowen	Boost Target	Market Perform	$635.00 ➝ $645.00	Low
7/20/2022	Cowen	Boost Target		$635.00 ➝ $645.00	Low
7/15/2022	Morgan Stanley	Boost Target	Equal Weight	$610.00 ➝ $619.00	Low
7/12/2022	Cantor Fitzgerald	Initiated Coverage	Neutral	$625.00	N/A
6/20/2022	Evercore ISI	Set Target		$635.00	Low
6/17/2022	Jefferies Financial Group	Downgrade	Sell	$536.00	Low
6/6/2022	Jefferies Financial Group	Initiated Coverage	Underperform	$536.00	High
6/3/2022	Wells Fargo & Company	Lower Target	Overweight	$750.00 ➝ $735.00	Low
6/3/2022	Morgan Stanley	Lower Target	Equal Weight	$620.00 ➝ $610.00	Low
5/31/2022	Argus	Boost Target	Buy	$680.00 ➝ $760.00	High
5/23/2022	SVB Leerink	Initiated Coverage	Outperform	$738.00	Medium
4/20/2022	Cowen	Boost Target		$640.00 ➝ $645.00	Low
4/20/2022	Cowen	Boost Target		$640.00 ➝ $645.00	Low
4/12/2022	Morgan Stanley	Boost Target	Equal Weight	$605.00 ➝ $632.00	Low
4/12/2022	Barclays	Boost Target	Overweight	$700.00 ➝ $745.00	Medium
2/11/2022	BMO Capital Markets	Reiterated Rating	Buy	$780.00	High
2/8/2022	Truist Financial	Lower Target	Buy	$754.00 ➝ $728.00	Low
2/8/2022	Oppenheimer	Lower Target	Outperform	$825.00 ➝ $775.00	Low
2/7/2022	Morgan Stanley	Boost Target	Equal Weight	$585.00 ➝ $605.00	Low
2/4/2022	BMO Capital Markets	Reiterated Rating	Buy	$780.00	Low
2/4/2022	Piper Sandler	Boost Target	Overweight ➝ Overweight	$690.00 ➝ $692.00	Low
1/31/2022	Truist Financial	Lower Target	Buy	$756.00 ➝ $754.00	Medium
1/18/2022	Morgan Stanley	Lower Target	Equal Weight	$617.00 ➝ $585.00	High
1/5/2022	Bank of America	Downgrade	Neutral ➝ Underperform	$675.00 ➝ $575.00	High
1/3/2022	Sanford C. Bernstein	Upgrade	Market Perform ➝ Outperform	$660.00	High
12/15/2021	Sanford C. Bernstein	Downgrade	Outperform ➝ Market Perform	$660.00	Low
12/14/2021	SVB Leerink	Reiterated Rating	Buy		Medium
12/13/2021	HC Wainwright	Reiterated Rating	Buy		High
12/8/2021	Wells Fargo & Company	Initiated Coverage	Overweight	$750.00	High
12/7/2021	Cowen	Initiated Coverage	Market Perform	$625.00	Low
12/6/2021	The Goldman Sachs Group	Initiated Coverage	Buy	$824.00	Medium
11/19/2021	BMO Capital Markets	Initiated Coverage	Outperform	$780.00	Low
11/10/2021	Cantor Fitzgerald	Boost Target	Positive ➝ Overweight	$700.00 ➝ $760.00	Medium
11/5/2021	SVB Leerink	Boost Target	Outperform	$798.00 ➝ $850.00	Medium
11/5/2021	Morgan Stanley	Boost Target	Equal Weight	$571.00 ➝ $617.00	Low
11/5/2021	Benchmark	Downgrade	Buy ➝ Hold		High
11/5/2021	HC Wainwright	Boost Target	Buy	$842.00 ➝ $844.00	Medium
10/26/2021	SVB Leerink	Boost Target	Outperform	$785.00 ➝ $798.00	Medium
10/22/2021	HC Wainwright	Boost Target	Buy	$831.00 ➝ $842.00	Low
10/12/2021	Morgan Stanley	Lower Target	Equal Weight	$606.00 ➝ $571.00	Low
10/4/2021	HC Wainwright	Reiterated Rating	Buy	$831.00	High
9/21/2021	BMO Capital Markets	Boost Target	Outperform	$669.00 ➝ $706.00	Low
9/15/2021	Piper Sandler	Boost Target	Overweight	$675.00 ➝ $690.00	Low
9/15/2021	Cantor Fitzgerald	Boost Target	Overweight	$670.00 ➝ $700.00	Medium
9/15/2021	HC Wainwright	Boost Target	Buy	$787.00 ➝ $831.00	Medium
9/9/2021	UBS Group	Initiated Coverage	Buy	$763.00	High
9/7/2021	Morgan Stanley	Boost Target	Equal Weight	$576.00 ➝ $606.00	Low
8/23/2021	Benchmark	Boost Target	Buy	$636.00 ➝ $727.00	Low
8/20/2021	HC Wainwright	Reiterated Rating	Buy	$787.00	Low
8/6/2021	Barclays	Boost Target	Overweight	$675.00 ➝ $705.00	Medium
8/6/2021	SVB Leerink	Boost Target	Outperform	$641.00 ➝ $725.00	High
8/6/2021	BMO Capital Markets	Boost Target	Outperform	$625.00 ➝ $669.00	High
8/6/2021	Oppenheimer	Boost Target	Outperform	$725.00 ➝ $825.00	Medium
8/5/2021	Piper Sandler	Boost Target	Overweight	$650.00 ➝ $675.00	High
8/2/2021	HC Wainwright	Boost Target	Buy	$729.00 ➝ $741.00	Low
7/23/2021	Royal Bank of Canada	Boost Target	Sector Perform	$629.00 ➝ $679.00	Low
7/8/2021	Benchmark	Boost Target	Buy	$590.00 ➝ $636.00	Low
6/29/2021	HC Wainwright	Initiated Coverage	Buy	$703.00	Low
5/7/2021	SVB Leerink	Lower Target	Outperform	$657.00 ➝ $641.00	Low
5/7/2021	Morgan Stanley	Boost Target	Equal Weight	$477.00 ➝ $495.00	Low
4/19/2021	Morgan Stanley	Lower Target	Equal Weight	$525.00 ➝ $477.00	Low
4/13/2021	Robert W. Baird	Reiterated Rating	Hold		Low
3/26/2021	SVB Leerink	Boost Target	Outperform	$655.00 ➝ $657.00	High
2/23/2021	Credit Suisse Group	Boost Target	Outperform	$753.00 ➝ $760.00	High
2/16/2021	Cantor Fitzgerald	Lower Target	Overweight	$696.00 ➝ $656.00	Low
2/8/2021	Morgan Stanley	Lower Target	Equal Weight	$553.00 ➝ $525.00	Medium
2/8/2021	Credit Suisse Group	Lower Target	Outperform	$758.00 ➝ $753.00	Medium
2/8/2021	Cowen	Lower Target	Outperform	$684.00 ➝ $565.00	High
2/8/2021	SVB Leerink	Boost Target	Outperform	$623.00 ➝ $640.00	High
1/25/2021	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$630.00	Medium
1/19/2021	Morgan Stanley	Boost Target	Equal Weight	$527.00 ➝ $553.00	Low
1/14/2021	Smith Barney Citigroup	Boost Target		$575.00 ➝ $584.00	Low
1/13/2021	Benchmark	Upgrade	Hold ➝ Buy	$590.00	Medium
1/8/2021	FIX	Upgrade	Neutral ➝ Buy	$635.00 ➝ $575.00	Medium
12/16/2020	Morgan Stanley	Lower Target	Equal Weight	$602.00 ➝ $527.00	Low
12/16/2020	Credit Suisse Group	Lower Target	Outperform	$737.00 ➝ $736.00	Medium
11/9/2020	Morgan Stanley	Lower Target	Equal Weight	$609.00 ➝ $602.00	High
11/6/2020	Truist Financial	Boost Target		$750.00 ➝ $770.00	Low
11/6/2020	Credit Suisse Group	Lower Target	Outperform	$745.00 ➝ $737.00	Low
11/6/2020	SVB Leerink	Boost Target	Outperform	$650.00 ➝ $653.00	Low
11/6/2020	BMO Capital Markets	Boost Target	Market Perform	$626.00 ➝ $630.00	Low
10/13/2020	Morgan Stanley	Lower Target	Equal Weight	$611.00 ➝ $609.00	Low
10/6/2020	SVB Leerink	Boost Target	Outperform	$629.00 ➝ $650.00	High
10/5/2020	Cantor Fitzgerald	Upgrade	Neutral ➝ Overweight	$690.00	High
10/1/2020	JPMorgan Chase & Co.	Reiterated Rating	Hold		High
8/20/2020	Benchmark	Downgrade	Buy ➝ Hold		High
8/7/2020	Credit Suisse Group	Boost Target	Outperform	$716.00 ➝ $725.00	Low
8/6/2020	Barclays	Boost Target		$615.00 ➝ $675.00	Low
8/6/2020	Morgan Stanley	Lower Target	Equal Weight	$619.00 ➝ $611.00	Low
8/6/2020	Oppenheimer	Boost Target	Outperform	$675.00 ➝ $725.00	Low
8/6/2020	Citigroup	Boost Target	Neutral	$585.00 ➝ $635.00	Low
8/6/2020	BMO Capital Markets	Boost Target	Outperform	$525.00 ➝ $626.00	Low
8/5/2020	The Goldman Sachs Group	Boost Target		$700.00 ➝ $800.00	Low
8/5/2020	Piper Sandler	Boost Target	Overweight	$630.00 ➝ $675.00	High
7/20/2020	Credit Suisse Group	Boost Target	Outperform	$700.00 ➝ $716.00	High
7/15/2020	Morgan Stanley	Boost Target	Equal Weight	$555.00 ➝ $619.00	Low
7/8/2020	SunTrust Banks	Upgrade	Hold ➝ Buy	$400.00 ➝ $750.00	Low
7/1/2020	Oppenheimer	Boost Target	Outperform	$625.00 ➝ $675.00	High
6/24/2020	Credit Suisse Group	Boost Target	Outperform	$605.00 ➝ $700.00	High
6/12/2020	Jefferies Financial Group	Boost Target	Buy	$657.00 ➝ $691.00	High
6/2/2020	Jefferies Financial Group	Reiterated Rating	Buy	$657.00	Low
6/2/2020	Cowen	Reiterated Rating	Hold	$584.00	Low
6/2/2020	Oppenheimer	Reiterated Rating	Buy	$625.00	Low
6/2/2020	Cantor Fitzgerald	Boost Target	Neutral	$400.00 ➝ $624.00	Low
5/28/2020	Barclays	Boost Target		$530.00 ➝ $615.00	High
5/27/2020	Cfra	Lower Target	Hold	$557.00 ➝ $549.00	Low
5/27/2020	SVB Leerink	Boost Target	Outperform	$622.00 ➝ $625.00	High
5/26/2020	SVB Leerink	Reiterated Rating	Buy	$622.00	Low
5/26/2020	Wells Fargo & Company	Upgrade	Equal Weight ➝ Overweight	$559.00 ➝ $734.00	High
5/6/2020	Robert W. Baird	Boost Target	Neutral ➝ Neutral	$487.00 ➝ $510.00	High
5/6/2020	BMO Capital Markets	Boost Target	Market Perform	$466.00 ➝ $525.00	High
5/6/2020	Royal Bank of Canada	Lower Target		$533.00 ➝ $524.00	Medium
5/6/2020	Piper Sandler	Boost Target		$550.00 ➝ $600.00	Low
5/6/2020	Morgan Stanley	Boost Target	Equal Weight	$409.00 ➝ $555.00	Medium
5/6/2020	Oppenheimer	Boost Target	Outperform	$525.00 ➝ $625.00	High
5/6/2020	Credit Suisse Group	Boost Target	Outperform	$596.00 ➝ $605.00	High
5/6/2020	The Goldman Sachs Group	Boost Target	Conviction-Buy	$636.00 ➝ $700.00	High
5/6/2020	SVB Leerink	Boost Target	Outperform	$604.00 ➝ $622.00	High
5/1/2020	Piper Sandler	Reiterated Rating	Overweight		Low
4/28/2020	Citigroup	Downgrade	Buy ➝ Neutral	$540.00 ➝ $575.00	High
4/19/2020	Benchmark	Initiated Coverage	Hold		Low
4/17/2020	BMO Capital Markets	Boost Target	Market Perform	$379.00 ➝ $466.00	High
4/17/2020	Benchmark	Upgrade	Hold ➝ Buy	$655.00	High
4/15/2020	Morgan Stanley	Lower Target	Equal Weight	$410.00 ➝ $409.00	Medium
4/15/2020	JPMorgan Chase & Co.	Boost Target	Neutral	$375.00 ➝ $429.00	Medium
4/8/2020	Benchmark	Initiated Coverage	Hold		Medium
4/7/2020	SVB Leerink	Boost Target	Outperform	$600.00 ➝ $604.00	Medium
4/6/2020	Wells Fargo & Company	Boost Target	Equal Weight	$370.00 ➝ $435.00	Low
3/31/2020	Wolfe Research	Initiated Coverage	Market Perform	$455.00	High
3/12/2020	Argus	Boost Target	Buy	$430.00 ➝ $540.00	High
3/11/2020	Oppenheimer	Boost Target	Outperform	$450.00 ➝ $525.00	Medium
3/4/2020	Cfra	Boost Target	Buy ➝ Hold	$460.00 ➝ $487.00	High
3/4/2020	Piper Sandler	Boost Target		$435.00 ➝ $500.00	High
2/28/2020	Cowen	Boost Target	Market Perform	$386.00 ➝ $495.00	High
2/28/2020	Citigroup	Boost Target	Buy	$420.00 ➝ $540.00	High
2/27/2020	Barclays	Initiated Coverage	Overweight	$530.00	High
2/26/2020	Sanford C. Bernstein	Upgrade	Market Perform ➝ Outperform	$500.00	Medium
2/26/2020	Credit Suisse Group	Boost Target	Top Pick ➝ Outperform	$420.00 ➝ $510.00	High
2/26/2020	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$410.00	High
2/25/2020	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$355.00 ➝ $492.00	High
2/24/2020	Evercore ISI	Upgrade	In-Line ➝ Outperform	$500.00	High
2/11/2020	Argus	Upgrade	Hold ➝ Buy	$430.00	Medium
2/7/2020	Evercore ISI	Initiated Coverage	Hold	$400.00	Low
2/7/2020	Morgan Stanley	Lower Target	Equal Weight	$411.00 ➝ $410.00	Low
2/7/2020	SunTrust Banks	Boost Target	Hold	$400.00	High
1/22/2020	Oppenheimer	Boost Target	Outperform	$430.00 ➝ $450.00	Low
1/17/2020	Morgan Stanley	Boost Target	Equal Weight	$387.00 ➝ $411.00	Low
1/14/2020	JPMorgan Chase & Co.	Reiterated Rating	Hold		High
12/23/2019	Raymond James	Initiated Coverage	Market Perform		N/A
12/13/2019	Credit Suisse Group	Upgrade	Neutral ➝ Outperform	$400.00	Low
12/9/2019	Credit Suisse Group	Upgrade	Neutral ➝ Outperform	$400.00	Low
11/12/2019	SunTrust Banks	Initiated Coverage	Hold	$360.00	Medium
11/11/2019	Evercore ISI	Reiterated Rating	Buy	$395.00	Low
11/6/2019	Citigroup	Upgrade	Neutral ➝ Buy	$340.00 ➝ $420.00	Low
11/6/2019	Oppenheimer	Lower Target		$480.00 ➝ $430.00	Low
11/6/2019	BMO Capital Markets	Boost Target	Market Perform	$344.00 ➝ $358.00	Medium
11/6/2019	JPMorgan Chase & Co.	Reiterated Rating	Hold	$375.00	Medium
11/6/2019	Credit Suisse Group	Boost Target	Neutral ➝ Neutral	$310.00 ➝ $340.00	Medium
10/16/2019	Bank of America	Initiated Coverage	Neutral	$325.00	Low
10/8/2019	Cowen	Set Target	Hold	$349.00	Low
10/8/2019	Piper Sandler Companies	Set Target	Buy	$435.00	Low
10/8/2019	BMO Capital Markets	Set Target	Hold	$344.00	Low
9/23/2019	Guggenheim	Upgrade	Neutral ➝ Buy	$355.00 ➝ $403.00	Low
8/7/2019	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$410.00	Low
8/7/2019	Credit Suisse Group	Lower Target	Neutral	$333.00 ➝ $325.00	Low
8/7/2019	BMO Capital Markets	Lower Target	Market Perform	$344.00	Low
7/29/2019	Cowen	Reiterated Rating	Hold	$353.00	Medium
6/21/2019	JPMorgan Chase & Co.	Reiterated Rating	Hold		Low
6/18/2019	Argus	Downgrade	Buy ➝ Hold		High
6/14/2019	JPMorgan Chase & Co.	Reiterated Rating	Hold		Low
6/11/2019	SVB Leerink	Set Target	Buy	$453.00	Low
5/23/2019	Citigroup	Lower Target	Neutral ➝ Neutral	$396.00 ➝ $340.00	Low
5/20/2019	Credit Suisse Group	Initiated Coverage	Neutral	$336.00	High

(Data available from 5/17/2019 forward)

News Sentiment Rating

0.82 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

40 very positive mentions
18 positive mentions
1 negative mentions
2 very negative mentions

Mentions as of

10/20/2023

20 very positive mentions
22 positive mentions
1 negative mentions
2 very negative mentions

Mentions as of

11/19/2023

39 very positive mentions
19 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

12/19/2023

44 very positive mentions
26 positive mentions
5 negative mentions
0 very negative mentions

Mentions as of

1/18/2024

50 very positive mentions
43 positive mentions
1 negative mentions
3 very negative mentions

Mentions as of

2/17/2024

35 very positive mentions
42 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

3/18/2024

23 very positive mentions
27 positive mentions
9 negative mentions
7 very negative mentions

Mentions as of

4/17/2024

48 very positive mentions
35 positive mentions
6 negative mentions
1 very negative mentions

Mentions as of

5/17/2024

Current Sentiment

Recent Stories by Sentiment

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Today's Range

Now: $982.29

$966.00

$982.77

50 Day Range

MA: $942.68

$883.20

$984.64

52 Week Range

Now: $982.29

$684.80

$998.33

Volume

386,557 shs

Average Volume

486,930 shs

Market Capitalization

$108.24 billion

P/E Ratio

29.02

Dividend Yield

N/A

Beta

0.17

Frequently Asked Questions

What sell-side analysts currently cover shares of Regeneron Pharmaceuticals?: The following equities research analysts have issued stock ratings on Regeneron Pharmaceuticals in the last year: 22nd Century Group, Inc., 500.com Limited, Argus, Bank of America Co., Barclays PLC, BMO Capital Markets, Canaccord Genuity Group Inc., Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, Evercore ISI, Guggenheim, Jefferies Financial Group Inc., Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, StockNews.com, TD Cowen, Truist Financial Co., UBS Group AG, VNET Group, Inc., Wells Fargo & Company, and Westpark Capital.
View the latest analyst ratings for REGN.
What is the current price target for Regeneron Pharmaceuticals?: 22 Wall Street analysts have set twelve-month price targets for Regeneron Pharmaceuticals in the last year. Their average twelve-month price target is $989.36, suggesting a possible upside of 0.7%. Royal Bank of Canada has the highest price target set, predicting REGN will reach $1,189.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $720.00 for Regeneron Pharmaceuticals in the next year.
View the latest price targets for REGN.
What is the current consensus analyst rating for Regeneron Pharmaceuticals?: Regeneron Pharmaceuticals currently has 1 sell rating, 4 hold ratings, 15 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for REGN.
What other companies compete with Regeneron Pharmaceuticals?: Other companies that are similar to Regeneron Pharmaceuticals include Vertex Pharmaceuticals, GSK, Sanofi, Bristol-Myers Squibb and Zoetis. Learn More about companies similar to Regeneron Pharmaceuticals.
How do I contact Regeneron Pharmaceuticals' investor relations team?: Regeneron Pharmaceuticals' physical mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company's listed phone number is (914) 847-7000 and its investor relations email address is [email protected]. The official website for Regeneron Pharmaceuticals is www.regeneron.com. Learn More about contacing Regeneron Pharmaceuticals investor relations.

Regeneron Pharmaceuticals - REGN Stock Price Target and Predictions

Analyst Price Target for REGN

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.82 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Regeneron Pharmaceuticals?

What is the current price target for Regeneron Pharmaceuticals?

What is the current consensus analyst rating for Regeneron Pharmaceuticals?

What other companies compete with Regeneron Pharmaceuticals?

How do I contact Regeneron Pharmaceuticals' investor relations team?